As of Dec 31, 2018
- Date of establishment March 1, 2013
- CapitalKRW42.2 billion
- Number. of shares 8.44 million
- Number. of employees1,533
-
2010’s
-
- 2019
- 12Dong-A ST reduces the size of 'Stillen Tablet' for gastritis.
- 10Dong-A ST cooperates with Ildong Pharmaceutical for the joint promotion of ‘Dong-A Gaster Tab.’
- 09Dong-A ST launches the IBA proton therapy device on the market.
- 09Dong-A ST releases the microarthroscopy ‘Troy’.
- 09Dong-A ST acquires authorization from Japan to market Darbepoetin-α biosimilar ‘DA-3880’, which is licensed out to SKK.
- 07Dong-A ST passes the surveillance inspection for the ISO37001 certification.
- 06Dong-A ST reduces the size of 'Stillen 2X Tablet' for gastritis.
- 03Dong-A ST releases the diabetes treatment 'Suganon' in an overseas market (India).
- 03Dong-A ST’s erectile dysfunction treatment, Zydena, is proven to improve 'post-micturition dribble’.
- 02Dong-A ST invites members of the public to join 'the 3rd Dong-A ST Open Innovation Research Project'.
- 01Dong-A ST signs a business agreement with the Dongdaemun Welfare Center for Disabilities to improve welfare for the disabled.
-
- 2018
- 11Developed the urban forest #1 with Seoul Metropolitan City and Forest for Life Foundation.
- 11Released ‘Dutavan Plus Tab.’ for the treatment of hair loss and benign prostatic hyperplasia.
- 10The growth hormone ‘Growtropin’ obtained the approval for post-opening stability.
- 08Signed the business agreement with Seoul Metropolitan City and Forest for Life Foundation for urban forest development.
- 08Signed the agreement with Takara Bio, Japan for introduction of oncolytic virotherapy as a new anticancer agent.
- 07 ‘ISO 37001’ certification for anti-bribery management systems
- 04Signed the joint sales agreement with CJ Healthcare for the diabetes treatments, ‘Suganon & Sugamet’.
- 02Completed the biopharmaceutical factory in Indonesia.
- 01Signed the license-out agreement of natural product medicine with NeuroBo Pharmaceuticals, USA.
- 01Signed the joint research agreement of cancer immunotherapy with AstraZeneca.
- 01Signed the joint development and licensing agreement of bispecific antibody cancer immunotherapy with ABL Bio.
-
- 2017
- 12Hosted the symposium to commemorate launching of Edarbi for hypertension treatment.
- 12Released the antihistamine, ‘Twolion Tab.’.
- 11Held the ‘declaration ceremony of CP reinforcement and ISO37001 introduction’.
- 11Dong-A ST and Takeda Pharmaceuticals Korea hosted the ceremony for Edarbi co-promotion.
- 10Released ‘Virreal Tab.’ for the treatment of Hepatitis B.
- 08Released ‘Togenon Tab.’ for the treatment of hypertension.
- 06Obtained CCM (Consumer-Centered Management) certification.
- 06Released ‘Jublia Topical Solution’ for the treatment of hand and toenail athlete’s foot.
- 03Dong-A ST and Dong-A Socio Holdings signed the MOU with ABL Bio for the development of antibody drug.
- 02Released ‘Dutavan Soft Cap.’ for the treatment of urination disorder.
- 02Released ‘Valvirus Tab.’ for the treatment of herpes zoster.
- 02Signed the joint research contract with Yonsei Medical Center for the development of ‘hereditary hearing loss’ treatment.
-
- 2016
- 10Promoted joint research for the development of next-generation anticancer drugs with Beactica of Sweden.
- 10Signed an MOU for the development and sales of a medical endoscope with Haesung Optics.
- 07Selected as a '2016 Innovative Pharmaceutical Company'.
- 07Selected as a company with an ‘excellent labor-management culture’.
- 05Signed an exclusive sales & marketing agreement for 'Jublia', a new topical nail fungus treatment with Kaken Pharmaceutical of Japan.
- 05Signed an agreement for the co-development of stem-cell treatment for IVH (Intra Ventricular Hemorrhage) with the Samsung Medical Center and MediPost.
- 05Released 'Sugamet SR', a new drug complex for treating diabetes.
- 04Signed a global licensing contract for 'Evogliptin' for the treatment of nonalcoholic steatohepatitis (NASH).
- 03Entered the energy drinks market in Taiwan with the canned drink Bacchus.
- 03Signed an export contract for 'Terizidon', an API for tuberculosis drugs, to China.
- 03Released 'Suganon Tablet', a new diabetes drug developed in-house.
- 02Awarded the Grand Prize of the Korea New Drug Awards for 'Suganon Tablet', a treatment for diabetes.
- 01Earned the 'AA' rating in the 2015 CP Rating by the Fair Trade Commission.
-
- 2015
- 12Hosted the 10th anniversary symposium for the launch of ‘Zydena’.
- 12Selected as an ‘excellent company’ in the bio sector in 2015.
- 12Awarded the Grand Prize in the ‘innovative new drug development’ category at the 2015 Medical Korea Awards.
- 12Earned the highest 'AA' rating in Korea in the 2015 CP Rating the by Fair Trade Commission.
- 12Released the 'Styrene 2X Tablet', a highly convenient treatment for gastritis.
- 12Hosted the 10th anniversary symposium for the release of ‘Zydena’.
- 11Granted FDA licensing approval for 'Teribone S.C. Inj. 56.5ug', a treatment for osteoporosis.
- 11Hosted a symposium to launch the 'Acelex Capsule', an osteoarthritis treatment.
- 11Senior researcher Jang Sun-woo received the formulation technology award at the 2015 International Conference of the KSPST.
- 10FDA approval of new drug application for 'Suganon', a diabetes treatment developed in-house.
- 09Released the 'Acelex Capsule' for the treatment of osteoarthritis.
- 07Signed a sales contract for the crystal genomics osteoarthritis treatment 'Acelex Capsule'.
- 07Signed a licensing contract for 'Evogliptin', a diabetes treatment, with GeroPharm of Russia.
- 06Hosted the launching event for ‘Zydena’ in Brazil.
- 04Vice President Kim Won-bae received the Creation Award of the Order of Science and Technology Merit.
- 04Approval of new drug application in Korea for the super bacteria targeting antibiotic 'Sivextro Tablet'.
- 04Signed an additional licensing contract for a diabetes drug with Eurofarma.
- 03Granted European marketing authorization for the super bacteria targeting antibiotic 'Sivextro Tablet'.
- 02Awarded the Technology Exporter Award for the super antibiotic 'Sivextro Tablet'.
- 01Hosted 'The First Bacchus Marathon' in Guatemala.
-
- 2014
- 09Signed an exclusive sales contract for 'Gonadopin NF' with FarmaSino.
- 07Signed a strategic alliance with Combiphar of Indonesia.
- 06US FDA approval of new drug application for the super bacteria targeting antibiotic 'Sivextro Tablet'.
- 04Held the groundbreaking ceremony for the technical support building at the Banwol factory.
- 03Released the tuberculosis drug 'Closerine' in the Chinese market.
- 01Signed a licensing contract for the biosimilar 'DA-3880' with SKK of Japan.
-
- 2013
- 12Released the erectile dysfunction treatment 'Zydena 75mg' in daily dosage form.
- 10Applied for the US FDA’s approval of ‘Tedizolid,’ a super-bacteria antibiotic.
- 08Released the 'Nenoma Tablet', Korea’s first premature ejaculation treatment.
- 06Released 'Talion Ophthalmic Solution'.
- 04FDA approval for clinical phase 2 of DA-9801, a diabetic neuropathy drug.
- 03Switched to a holding company system. Divided into Dong-A Socio Holdings, Dong-A Pharmaceutical, and Dong-A ST.
-
- 2012
- 09Held groundbreaking ceremony for Dong-A Meiji Bio Plant in Song-do
- 09Listed Dong-A PharmTech on the KOSDAQ market
-
- 2011
- Hepatitis B drug LYII7 earned world-class certification (Ministry of Knowledge Economy)
- 12Unveiled new natural-material drug no.3, gastric-emptying accelerator Motilitone
- 04Recruited employees for the 100th time
- 02Posted South Korean pharmaceutical industry record sales of over KRW900 billion
-
- 2010
- 09Acquired the pharmaceutical raw-material company Samchully Pharmaceutical and renamed it ST Pharm
- 08The superbacteria antibiotic Tedizolid entered phase 3 clinical trials in the U.S.
- 06Signed a comprehensive business agreement with GSK
-
-
2000’s
-
- 2009
- 11Zydena entered phase 3 clinical trials in the U.S.
-
- 2007
- 03Signed a license agreement with Trius Therapeutics in the U.S.on worldwide market development and sale regarding the superbacteria-targeting antibiotic Tedizolid
-
- 2005
- 12Unveiled new drug no. 2, erectile dysfunction drug Zydena
-
- 2003
- Renamed Dong-A Glass Co. Soo Seok Co.
- 11Chairman Kang Shin-ho sworn in as FKI Chairman
-
- 2002
- Posted South Korean pharmaceutical industry record sale of over KRW500 billion
- 12Unveiled natural-material drug no.1, gastritis drug Stillen
- 09Established Dong-A PharmTech
-
- 2000
- 12Banwol Plant certified as BGMP-compliant
- 01Cheonan Plant certified as KGMP-compliant and constructed
-
-
1980-1990's
-
- 1998
- 07Launched the university student long march through the national land
-
- 1995
- Established Suzhou Boik Beverage Co. in China
- Bacchus sales posted over KRW100 billion
-
- 1992
- 03Renamed Dong-A Food Dong-A Otsuka
-
- 1990
- 01Established Dong-A America in the U.S.
-
- 1989
- 11Established Qingdao Jina Glass Co. in China
-
- 1988
- 11Constructed the industry’s first and advanced KGLP research center in Sanggal
-
- 1987
- Exports posted over USD10 million
- 11Developed the country’s first AIDS diagnosis reagent
- 05Dong-A Food unveiled Pocari Sweat
-
- 1985
- 04Designated as the industry’s first KGMP company no. 1
-
- 1983
- 07Established Yongma Logis Co., acquired a transport business license.
- 02Constructed an enzyme and raw-material synthesis plant in Banwol
-
- 1981
- 07Began to export Bacchus-D to the U.S
-
- 1980
- 05Constructed the country’s first GMP plant in Anyang
-
-
1930-1970's
-
- 1979
- 08Successfully synthesized the latest semi-synthetic penicillin Talampicillin
- 03Founded Dong-A Food (spun off from Dong-A Pharmaceutical Food Division); produced Oran-C, Cocas, Narangd Cider, etc.
-
- 1978
- Established Dong-a Glass Co.
-
- 1977
- 07Launched a research center
-
- 1970'
- 02Went public, increased capital to KRW750 million
-
- 1967
- Sales rose to no. 1 in the domestic pharmaceutical industry
-
- 1963
- 08Began to produce the comprehensive nutritious tonic Bacchus-D
-
- 1960
- Began to produce the broad-spectrum antibiotic Kanamycin
-
- 1959
- 09Began to recruit employees openly
-
- 1958
- Constructed a modern-style plant and office in Yongdu-dong, Dongdaemun-gu, Seoul
-
- 1949
- 08Renamed the company Dong-A Pharmaceutical Co.
-
- 1932
- 12Launched wholesale business for medicines and hygienic materials in Junghak-dong, Jongno-gu, Seoul
-